FCE 22101 is a new penem antibiotic synthesized by Farmitalia Carlo Erba Laboratories, Milan, Italy. It is bactericidal in its mode of action and has a broad antibacterial spectrum which includes gram-positive and gram-negative aerobic and anaerobic bacteria (3) . It is resistant to enzymatic inactivation by a wide range of beta-lactamases.
The purpose of the present study was to determine the in vitro activity of FCE 22101 against a variety of anaerobic bacteria recently isolated from human infections. Its activity was compared with those of benzylpenicillin, piperacillin, cefoxitin, imipenem, clindamycin, metronidazole, chloramphenicol, vancomycin, fusidic acid, and bacitracin.
The strains tested (Table 1) were isolated from a variety of clinical specimens submitted to the National Bacteriological Laboratory and the Huddinge University Hospital, Stockholm, Sweden, during 1985 and 1986.
All strains were identified by the criteria of Holdeman et al. (2) . The antimicrobial susceptibility tests were performed by the method of Dornbusch et al. (1) . The strains were grown in rubber-stoppered tubes containing prereduced chopped meat broth with glucose. The antibacterial susceptibility testing was performed on PDM-ASM agar (AB Biodisc, Solna, Sweden) with the addition of 5% defibrinated horse blood. The The in vitro activity of antimicrobial agents against anaerobic cocci is shown in Table 1 . All of these strains were susceptible to FCE 22101, benzylpenicillin, piperacillin, and imipenem at 0.016 to 0.5 mg/liter. All of these strains were also susceptible to cefoxitin, with only four isolates having MICs of 16 mg/liter. All of these isolates were susceptible to chloramphenicol, clindamycin, and metronidazole.
All Propionibacterium acnes strains were susceptible to the antimicrobial agents tested (Table 1) . FCE 22101, benzylpenicillin, and imipenem were the most active agents tested. These drugs were more active against P. acnes than were piperacillin, cefoxitin, clindamycin, and chloramphenicol. metronidazole, and chloramphenicol were active against all Bacteroides species (other than B. fragilis) tested. Most fusobacteria were susceptible to the beta-lactam antibiotics tested (Table 1) . Four Fusobacterium nucleatum strains were resistant to benzylpenicillin and piperacillin (MIC, -128 mg/liter). FCE 22101 and imipenem were the most active beta-lactams tested against the fusobacteria. Most strains showed low clindamycin, metronidazole, and chloramphenicol MICs.
The in vitro data presented in this paper indicate that FCE 22101 is a promising new antimicrobial agent which may be useful in the treatment and prophylaxis of anaerobic infections. In planning therapy of an infection which appears to be caused by anaerobic bacteria, it is appropriate to consider that most infections are caused by both anaerobic and aerobic bacteria (4) . Therefore, antimicrobial agents such as FCE 22101, effective against both anaerobes and aerobes, may be useful, especially in the treatment of intra-abdominal infections and genital tract infections of females. FCE 22101 is a promising agent that warrants further investigations to determine whether it will be useful in the antimicrobial therapy of anaerobic infections.
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